Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat pilot study in adults with sickle cell disease
NL-OMON22508Active, not recruiting
- Sponsor
- Julius Clinical
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mitapivat in sickle cell disease (SCD), sickle cell anemia (SCA) and Hemoglobin S/beta-thalassemia (HbS/β-thalassemia), sponsored by Julius Clinical. Primary endpoints: Change in point of sickling and Safety and tolerability. Started May 2020; status: active, not recruiting.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)sickle cell anemia (SCA)Hemoglobin S/beta-thalassemia (HbS/β-thalassemia)
Beyond the preview
Go deeper on NL-OMON22508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22508.